Trial Profile

ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 08 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

29 May 2026 Planned initiation date changed from 1 Dec 2018 to 1 Oct 2018.
08 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
03 Oct 2018 Planned initiation date changed from 1 Aug 2018 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com